HUP9903918A2 - Fibrózis gátlására alkalmas szomatosztatin agonistát tartalmazó gyógyszerkészítmények - Google Patents

Fibrózis gátlására alkalmas szomatosztatin agonistát tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9903918A2
HUP9903918A2 HU9903918A HUP9903918A HUP9903918A2 HU P9903918 A2 HUP9903918 A2 HU P9903918A2 HU 9903918 A HU9903918 A HU 9903918A HU P9903918 A HUP9903918 A HU P9903918A HU P9903918 A2 HUP9903918 A2 HU P9903918A2
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
compositions containing
inhibiting fibrosis
somatostatin agonist
agonist useful
Prior art date
Application number
HU9903918A
Other languages
English (en)
Inventor
Michael D. Culler
Philip G. Kasprzyk
Original Assignee
Biomeasure Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomeasure Incorporated filed Critical Biomeasure Incorporated
Publication of HUP9903918A2 publication Critical patent/HUP9903918A2/hu
Publication of HUP9903918A3 publication Critical patent/HUP9903918A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

A találmány szőmatősztatin vagy egy szőmatősztatin agőnistaalkalmazására vőnatkőzik fibrózis gátlására alkalmasgyógyszerkészítmények előállítására. A találmány szerinti szőmatősztatint vagy egy szőmatősztatinagőnistát tartalmazó gyógyszerkészítmények különösen alkalmasak avesében, a tüdőben, a májban, a bőrön, a közpőnti idegrendszerben, acsőntőzatban vagy a csőntvelőben, a kardiővaszkűláris rendszerben, egyendőkrin szervben vagy a gasztőrintesztinális rendszerben bekövetkezőfibrózis gátlására. ŕ
HU9903918A 1996-08-30 1997-08-27 Pharmaceutical compositions containing somatostatin agonist useful for inhibiting fibrosis HUP9903918A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70579096A 1996-08-30 1996-08-30

Publications (2)

Publication Number Publication Date
HUP9903918A2 true HUP9903918A2 (hu) 2000-04-28
HUP9903918A3 HUP9903918A3 (en) 2000-07-28

Family

ID=24834961

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903918A HUP9903918A3 (en) 1996-08-30 1997-08-27 Pharmaceutical compositions containing somatostatin agonist useful for inhibiting fibrosis

Country Status (13)

Country Link
US (3) US6268342B1 (hu)
EP (2) EP1574219A3 (hu)
JP (2) JP2001500483A (hu)
CN (1) CN1229357A (hu)
AT (1) ATE322905T1 (hu)
AU (2) AU3215597A (hu)
CA (1) CA2264309A1 (hu)
DE (1) DE69735674T2 (hu)
ES (1) ES2258282T3 (hu)
HU (1) HUP9903918A3 (hu)
PL (1) PL331922A1 (hu)
WO (2) WO1998008528A1 (hu)
ZA (1) ZA977783B (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3215597A (en) * 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
EP1291022A1 (en) * 1998-07-30 2003-03-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Methods of using lanreotide, a somatostatin analogue
US6150333A (en) * 1998-07-30 2000-11-21 Biomeasure, Inc. Methods of using a somatostatin analogue
NZ509348A (en) * 1998-07-30 2004-02-27 Sod Conseils Rech Applic Use of a somatostatin analogue Lanreotide
IES990700A2 (en) * 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
AU2001272100A1 (en) 2000-03-09 2001-09-17 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
DE60226419D1 (de) 2001-03-08 2008-06-19 Univ Tulane Somatostatin-antagonisten
MXPA03009048A (es) 2001-04-09 2004-02-12 Univ Tulane Agonistas de la somatostatina.
AU2002324701A1 (en) * 2001-08-14 2003-03-03 Japan Tobacco, Inc. Gene expression profiles in glomerular diseases
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
AU2002359359A1 (en) * 2001-12-28 2003-07-24 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
WO2004039403A1 (ja) * 2002-10-31 2004-05-13 Senju Pharmaceutical Co., Ltd. 角膜障害治療剤
US20050043272A1 (en) * 2003-07-11 2005-02-24 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP1522311A1 (fr) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
US20070078109A1 (en) * 2004-02-13 2007-04-05 David Platt Compositions and methods used to treat acne and candida
WO2005082844A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Treatment of diseases by using a somatostatin receptor agonist
WO2005082845A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Novel therapies with somatostatin receptor agonists
SI1734970T1 (sl) 2004-03-12 2015-04-30 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo FXR ligandov
EP1773128A2 (en) * 2004-08-02 2007-04-18 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
US8597646B2 (en) 2005-10-25 2013-12-03 The Johns Hopkins University Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
US8454952B2 (en) 2006-03-13 2013-06-04 The Johns Hopkins University Augmentation of endothelial thromboresistance
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
FR2907682B1 (fr) * 2006-10-26 2012-12-07 Vincience Composition cosmetique et/ou pharmaceutique comprenant comme principe actif au moins un peptide et utilisation de ce peptide.
WO2009033781A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CN102112145B (zh) 2008-06-12 2014-07-30 辛它可辛有限公司 神经内分泌病的抑制
EP2310029B1 (en) 2008-06-12 2019-04-03 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of cancer
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
EP3117709B1 (en) 2010-03-12 2018-08-01 Genzyme Corporation Combination therapy for treating breast cancer
WO2011151782A1 (en) 2010-06-02 2011-12-08 Preglem Sa A role for somatostatin to modulate initiation of follicular growth in the human ovary
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique
JP5886212B2 (ja) 2010-12-27 2016-03-16 Ｌｓｉｐファンド運営合同会社 ｉＰＳ細胞とその製造法
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
WO2014070965A2 (en) 2012-11-01 2014-05-08 Ipsen Pharma S.A.S Somatostatin analogs and dimers thereof
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
RS56711B1 (sr) 2013-02-07 2018-03-30 Scifluor Life Sciences Inc Fluorirani antagonisti integrina
WO2014130648A1 (en) 2013-02-20 2014-08-28 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
KR20170141757A (ko) 2015-04-30 2017-12-26 사이플루어 라이프 사이언시즈, 인크 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도
WO2016187312A1 (en) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
US10118929B2 (en) 2016-04-27 2018-11-06 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
GB201816637D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd Selective somatostatin receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR862206B (en) * 1985-09-12 1986-12-31 Univ Tulane Therapeutic somatostatin analogs
US4904642A (en) * 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
GB8716324D0 (en) 1987-07-10 1987-08-19 Sandoz Ltd Organic compounds
DE3845000C2 (de) 1987-07-10 1998-11-19 Novartis Ag Anwendung von Octreotid zur Behandlung von Brustkrebs
JP2882679B2 (ja) 1989-04-26 1999-04-12 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 線状ソマトスタチン類似体
HU207104B (en) 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
AU2092597A (en) * 1996-03-07 1997-09-22 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
AU3215597A (en) * 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist

Also Published As

Publication number Publication date
CA2264309A1 (en) 1998-03-05
JP2001500483A (ja) 2001-01-16
EP0938328A4 (en) 2002-08-28
ES2258282T3 (es) 2006-08-16
HUP9903918A3 (en) 2000-07-28
CN1229357A (zh) 1999-09-22
EP0938328A1 (en) 1999-09-01
US20050222025A1 (en) 2005-10-06
DE69735674D1 (de) 2006-05-24
US6268342B1 (en) 2001-07-31
PL331922A1 (en) 1999-08-16
DE69735674T2 (de) 2007-04-05
EP1574219A3 (en) 2006-04-26
JP2008074857A (ja) 2008-04-03
EP0938328B1 (en) 2006-04-12
ZA977783B (en) 1999-03-01
WO1998008528A1 (en) 1998-03-05
EP1574219A2 (en) 2005-09-14
US6787521B2 (en) 2004-09-07
US20010011072A1 (en) 2001-08-02
US7238666B2 (en) 2007-07-03
AU726731B2 (en) 2000-11-16
AU3215597A (en) 1998-03-19
AU4149097A (en) 1998-03-19
ATE322905T1 (de) 2006-04-15
WO1998008529A1 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
HUP9903918A2 (hu) Fibrózis gátlására alkalmas szomatosztatin agonistát tartalmazó gyógyszerkészítmények
ITRM990338A0 (it) Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria.
HUP0000492A3 (en) N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
BR9710636A (pt) Análogo de somatostatina ciclizada da espinha dorsal, uso do mesmo, composição farmacêutica,e , processo de tratamento de distúrbios endócrinos, neoplasmas ou distúrbios metabólicos.
SI0951466T1 (sl) Cikloalkili, laktami, laktoni in sorodne spojine, farmacevtske zmesi, ki jih vsebujejo, in metode inhibicije sproščanja beta-amiloidnega peptida in/ali njegove sinteze z uporabo takih spojin
ZA981627B (en) Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
AU3445697A (en) New use of xylitol and pharmaceutical compositions therefor
EP1045636A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING THE SAME FOR TREATING FAILURE MYOCARDIAL TISSUES
HUP9901410A3 (en) Nitrile derivatives as inhibitors of tumor necrosis factor alpha and pharmaceutical compositions containing them
ID18663A (id) Komposisi farmasi berlapis enterik
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
GR3036253T3 (en) Cyclopropyl alkanoic acid derivatives
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
BR9804437A (pt) Compostos para a osteoporose
IL129477A0 (en) N-(aryl/heteroaryl)amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
BR9702200A (pt) Compostos bicíclicos-aromáticos composição farmacéutica composição cosmética e utilização de uma composição cosmética
AU2108500A (en) Galenic formulation containing biotin
AU1843397A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
AU1727797A (en) Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
HUP0003679A3 (en) Use of pkc inhibitors for the preparation of pharmaceutical compositions treating cardiovascular diseases
BR9814945A (pt) Utilização de fanquinona para o tratamento de doença de alzheimer, composição farmacêutica e kit
BG102661A (en) Benzo/o/quinolysine derivatives, their preparation and application as 5a-reductase inhibitors
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
IL121096A0 (en) Pharmaceutical compositions for the treatment of liver disease